Literature DB >> 22262800

Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.

Isao Tawara1, Yaping Sun, Chen Liu, Tomomi Toubai, Evelyn Nieves, Rebecca Evers, Mariem Alrubaie, Nathan Mathewson, Hiroya Tamaki, Pavan Reddy.   

Abstract

IL-10 is a key immune-regulatory cytokine, and its gene polymorphisms correlate with severity of clinical GVHD. IL-10 is made by a variety of donor and host cells, but the functional relevance of its source and its role in the biology of acute GVHD are not well understood. We used preclinical models to examine the relevance of IL-10(-/-) in donor and host cellular subsets on the severity of GVHD. IL-10(-/-) in host tissues or in the donor grafts did not alter donor Teff-mediated severity of GVHD. Furthermore, neither host-derived nor donor Teff-derived IL-10 was required for regulation of GVHD by WT CD4(+)CD25(+) donor Tregs. By contrast, Treg-derived IL-10, although not obligatory, was necessary for optimal reduction of GVHD by mature donor Tregs. Importantly, IL-10 from donor BM grafts was also critical for optimal donor Treg-mediated suppression of GVHD. Together, these data suggest that IL-10 does not contribute to the induction of GVHD severity by the Teffs. However, donor BM graft and Treg-derived IL-10 are important for donor Treg-mediated suppression of GVHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262800      PMCID: PMC3317273          DOI: 10.1189/jlb.1011510

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  50 in total

1.  IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells.

Authors:  Pedro L Vieira; Jillian R Christensen; Sophie Minaee; Emma J O'Neill; Franck J Barrat; André Boonstra; Thomas Barthlott; Brigitta Stockinger; David C Wraith; Anne O'Garra
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.

Authors:  J Cavet; P G Middleton; M Segall; H Noreen; S M Davies; A M Dickinson
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

Review 3.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

4.  Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD.

Authors:  Yuji Miura; Christopher J Thoburn; Emilie C Bright; Weiran Chen; Shinji Nakao; Allan D Hess
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

5.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

6.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

7.  Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Kelli P A MacDonald; Vanessa Rowe; Cheryl Filippich; Ranjeny Thomas; Andrew D Clouston; Joseph K Welply; Derek N J Hart; James L M Ferrara; Geoffrey R Hill
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

8.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

9.  CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.

Authors:  P A Taylor; R J Noelle; B R Blazar
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  13 in total

Review 1.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

2.  Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.

Authors:  Ludovic Belle; Kimberle Agle; Vivian Zhou; Cheng Yin-Yuan; Richard Komorowski; Daniel Eastwood; Brent Logan; Jie Sun; Nico Ghilardi; Daniel Cua; Calvin B Williams; Melanie Gaignage; Reece Marillier; Jacques van Snick; William R Drobyski
Journal:  Blood       Date:  2016-08-03       Impact factor: 22.113

3.  Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.

Authors:  Kaifeng Lisa Lin; LeShara M Fulton; Matthew Berginski; Michelle L West; Nicholas A Taylor; Timothy P Moran; James M Coghill; Bruce R Blazar; James E Bear; Jonathan S Serody
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

4.  Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality.

Authors:  Celalettin Ustun; Todd E DeFor; Fatma K Karadag; Hyun Don Yun; Sunita Nathan; Claudio G Brunstein; Bruce R Blazar; Daniel J Weisdorf; Shernan G Holtan; Khalid Amin
Journal:  Blood Adv       Date:  2020-05-26

5.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

6.  A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease.

Authors:  Vivian Zhou; Kimberle Agle; Xiao Chen; Amy Beres; Richard Komorowski; Ludovic Belle; Carolyn Taylor; Fenlu Zhu; Dipica Haribhai; Calvin B Williams; James Verbsky; Wendy Blumenschein; Svetlana Sadekova; Eddie Bowman; Christie Ballantyne; Casey Weaver; David A Serody; Benjamin Vincent; Jonathan Serody; Daniel J Cua; William R Drobyski
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

7.  Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.

Authors:  Supinya Iamsawat; Anusara Daenthanasanmak; Jessica Heinrichs Voss; Hung Nguyen; David Bastian; Chen Liu; Xue-Zhong Yu
Journal:  J Immunol       Date:  2018-09-21       Impact factor: 5.422

Review 8.  Management of inflammation in cardiovascular diseases.

Authors:  Sumanta Kumar Goswami; Prabhat Ranjan; Roshan Kumar Dutta; Suresh Kumar Verma
Journal:  Pharmacol Res       Date:  2021-09-23       Impact factor: 7.658

9.  The role of regulatory T cells in the biology of graft versus host disease.

Authors:  Amy J Beres; William R Drobyski
Journal:  Front Immunol       Date:  2013-06-24       Impact factor: 7.561

Review 10.  Oral complications in hematopoietic stem cell recipients: the role of inflammation.

Authors:  T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema
Journal:  Mediators Inflamm       Date:  2014-04-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.